Matthew T. Huggett

Matthew T. Huggett

Auto-generated profile, based on publicly available information

Matthew T. Huggett

Gastroenterology, St James’ University Hospital, The Leeds Teaching Hospitals NHS Foundation Trust, Leeds, Leeds, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2022 in Surgical Endoscopy
Verified
Journal Article
Open access
PDF file
WOWei On
Wei On
MHMatthew T. Huggett
Matthew T. Huggett
AYAlistair Young
Alistair Young
JPJames Pine
James Pine
ASAndrew Smith
Andrew Smith
BPBharat Paranandi
Bharat Paranandi
Background: Endoscopic ultrasound guided gastrojejunostomy (EUS-GJ) with lumen apposing metal stents has recently emerged as a viable option, as an alternative to surgical gastrojejunostomy and endoscopic enteral stenting, for managing gastric outlet obstruction (GOO). We aim to perform a retrospective analysis of the efficacy, safety and outcomes of EUS-GJ performed at three tertiary institutions in the United Kingdom. Methods: Consecutive patients who underwent EUS-GJ between August 2018 and March 2021 were identified from a prospectively maintained database. Data were obtained from interrogation of electronic health records. Results: Twenty five patients (15 males) with a median age of 63 years old (range 29–80) were included for analysis. 88% (22/25) of patients had GOO due to underlying malignant disease. All patients were deemed surgically inoperable or at high surgical risk. Both technical and clinical success were achieved in 92% (23/25) of patients. There was an improvement in the mean Gastric Outlet Obstruction Scoring System scores following a technically successful EUS-GJ (2.52 vs 0.68, p < 0.01). Adverse events occurred in 2/25 patients (8%), both due to stent maldeployment necessitating endoscopic closure of the gastric defect with clips. Long-term follow-up data were available for 21 of 23 patients and the re-intervention rate was 4.8% (1/21) over a median follow-up period of 162 (range 5–474) days. Conclusion: EUS-GJ in carefully selected patients is an effective and safe procedure when performed by experienced endoscopists.

31 August 2022 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Open access
PDF file
PCPuneet Chhabra
Puneet Chhabra
WOWei On
Wei On
BPBharat Paranandi
Bharat Paranandi
MHMatthew T. Huggett
Matthew T. Huggett
NRNaomi Robson
Naomi Robson
Nadeem Akhter TehamiNadeem Akhter Tehami
Nadeem Akhter Tehami
Puneet Chhabra, Wei On, Bharat Paranandi, Matthew T. Huggett, Naomi Robson, Mark Wright, Ben Maher, Nadeem Tehami. Ann Hepatobiliary Pancreat Surg -0001;0:. https://doi.org/10.14701/ahbps.22-019

10 March 2026 in Frontline Gastroenterology
Verified
Journal Article
Open access
PDF file
MHMatthew T Huggett
Matthew T Huggett
MNManu Nayar
Manu Nayar
JLJohn Leeds
John Leeds
NONeil O’MOrain
Neil O’MOrain
PBPradeep Bhandari
Pradeep Bhandari
SESimon M Everett
Simon M Everett
Background On 20 December 2025, Boston Scientific initiated an urgent field safety notice and recall of selected Hot AXIOS lumen-apposing metal stent (LAMS) systems (6×8 mm, 8×8 mm and 20×10 mm) following reports of deployment and expansion failures at the time of delivery. These devices are widely used in the UK for therapeutic endoscopic ultrasound (T-EUS), including pancreatic fluid collection (PFC) drainage, EUS-guided gallbladder drainage (EUS-GBD), choledochoduodenostomy (EUS-CDD), gastrojejunostomy (EUS-GJ) and EUS-Directed transgastric endoscopic retrograde cholangio pancreatography (ERCP) (EDGE) procedures. The recall has immediate implications for urgent and complex interventions. Methods The British Society of Gastroenterology (BSG) Endoscopy Committee convened an expert working group comprising members of the committee and UK T-EUS leaders. Using evidence synthesised for the forthcoming BSG T-EUS Guidelines, the group developed consensus-based interim recommendations addressing alternative devices, technical strategies, salvage of stent maldeployment and governance measures. All recommendations achieved 100% agreement and were ratified by the BSG Endoscopy Committee. Results For PFC drainage and EUS-GBD, unaffected AXIOS sizes and alternative LAMS (eg, HOT SPAXUS, Z-EUS) remain viable options, with plastic stents or percutaneous approaches as adjuncts. The greatest impact is in malignant distal biliary obstruction, where withdrawal of 6×8 mm and 8×8 mm devices necessitates consideration of 10×10 mm LAMS in selected cases, alternative LAMS, tubular self-expanding metal stents, EUS-rendezvous, EUS-guided hepaticogastrostomy or antegrade stenting. For EUS-GJ and EDGE, the use of smaller LAMS or staged techniques is advised. Practical guidance for recognition and rescue of LAMS maldeployment is summarised, alongside recommendations for enhanced governance, regional collaboration and prospective data capture. Conclusion This interim BSG position statement provides pragmatic, consensus-driven guidance to maintain safe and effective T-EUS practice in the UK following the AXIOS recall. These recommendations support clinical decision-making during this period of device limitation and complement forthcoming national guidelines.

1 February 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MHMatthew T. Huggett
Matthew T. Huggett
HPHelen Passant
Helen Passant
CHChris Hurt
Chris Hurt
SPStephen Paul Pereira
Stephen Paul Pereira
JBJohn A. Bridgewater
John A. Bridgewater
SMSomnath Mukherjee
Somnath Mukherjee
272 Background: The ABC-02 trial has defined the standard therapy for patients with advanced biliary tract cancer (ABC), however outcome in an unselected patient population in the UK has not been described. We report the outcome of a series of patients with ABC from two large UK cancer networks. Methods: We retrospectively reviewed all cases of ABC presenting to two UK cancer networks over a 9-year period. Patients with a diagnosis recorded under anatomical site (liver, gallbladder or biliary tree) or histological diagnosis (cholangiocarcinoma or adenocarcinoma, liver), were included. Any patients who had surgery with curative intent were excluded. Overall survival (OS) and factors influencing OS were assessed. For the analysis, chemotherapy regimens were considered as: (i) gemcitabine (G)-based vs. non-G-based, (ii) platinum (P)-based vs. non-P-based and (iii) fluoropyrimidine (F)-based vs. non-F-based. Results: 402 patients were available for analysis. The median OS was 6.2 months. On univariate analysis, age ≥ 70 years (p=0.047), advanced disease stage (p<0.001), gall bladder primary (p=0.033), poor performance status (p<0.001) and lack of chemotherapy (p<0.001) were associated with worse outcome. Survival was superior in the 36.4% of patients who received palliative chemotherapy (12.5 versus 4.3 months; p<0.001). In patients receiving chemotherapy, on multivariate analysis males had higher mortality than females (HR=1.71; p=0.006) and stage 4 disease had a higher mortality (HR=2.62; p=0.002) than stage 1-2 disease. Patients who did not receive F-based regimens (HR=5.12; p=0.022) or G-based regimens (HR=5.01; p=0.021) had a higher mortality, whereas the effect of P-containing regimens was of borderline significance (HR=2.23; p=0.086). Sites, age, and multi-agent regimens were not significant. Conclusions: This is the first retrospective series from the UK and one of the largest population-based studies in ABC and confirms the benefit of palliative chemotherapy in an unselected group of patients. F-based regimens appear to be as effective as G-based treatments.

9 June 2023 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
YIYervant Ichkhanian
Yervant Ichkhanian
TATaha Ashraf
Taha Ashraf
SASpandana Alluri
Spandana Alluri
SSStephen Simmer
Stephen Simmer
MPMatthew Peller
Matthew Peller
TZTobias Zuchelli
Tobias Zuchelli

9 June 2023 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
YIYervant Ichkhanian
Yervant Ichkhanian
TATaha Ashraf
Taha Ashraf
SASpandana Alluri
Spandana Alluri
SSStephen Simmer
Stephen Simmer
MPMatthew Peller
Matthew Peller
TZTobias Zuchelli
Tobias Zuchelli